Abstract:In their article on statin therapy for patients with coronary artery disease, [[1]Nakamura M. Yamashita T. Yajima J. Oikawa Y. Ogasawara K. Sagara K. Koike A. Kirigaya H. Nagashima K. Otsuka T. Uejima T. Funada R. Matsuno S. Suzuki S. Sawada H. et al.Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease.J Cardiol. 2011; 57: 172-180Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar] Nakamura and colleagues discussed the effect of statin therapy on all-cause mortality, target lesion revascularization (TLR), and a composite endpoint of death, myocardial infarction, and readmission for heart failure among a prespecified subgroup of patients undergoing percutaneous coronary intervention (PCI). Their findings showed a discrepancy between mortality and cardiovascular events. Statin therapy decreased the risk of fatal events, but not TLR, or the composite triple endpoint. However, we think that these results need to be cautiously interpreted because a not ideal adjustment of confounding by indication together with insufficient power may have affected the validity and precision of their effect estimates. Although the association between statin therapy and all-cause mortality among PCI-patients were statistically significant in this study, the reported magnitude of protection, in our opinion, may have been overestimated. Based on a cohort of PCI-patients with similar enrollment period (February 2004 to May 2004; February 2006 to July 2006) from the US National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry, 83% of whom received at least one drug-eluting stent, we found a reduction of 42% in all-cause mortality [[2]Zhang Z.J. Marroquin O.C. Weissfeld J.L. Stone R.A. Mulukutla S.R. Williams D.O. Selzer F. Kip K.E. Beneficial effects of statins after percutaneous coronary intervention.Eur J Cardiovasc Prev Rehabil. 2009; 16: 445-450Crossref PubMed Scopus (15) Google Scholar] as compared with 73% in their study. It is noteworthy that up to today no clinical trials have confirmed the mortality benefit of statins among PCI-patients [[3]Zhang Z.J. Cheng Q. Jiang G.X. Marroquin O.C. Statins in prevention of repeat revascularization after percutaneous coronary intervention—a meta-analysis of randomized clinical trials.Pharmacol Res. 2010; 61: 316-320Crossref PubMed Scopus (9) Google Scholar]. On the other hand, their evidence of lack of effect on TLR or the composite endpoint of cardiac events seems unreliable. Given the observed effect on mortality, it could not be explained only by false negatives due to small sample size. Based on the NHLBI Dynamic Registry, we found post-discharge statin therapy significantly reduced the need for repeat revascularization after adjusting for a wide array of covariates via propensity score models (hazard ratio: 0.74, 95% confidence interval: 0.56–1.00, P = 0.05) [[2]Zhang Z.J. Marroquin O.C. Weissfeld J.L. Stone R.A. Mulukutla S.R. Williams D.O. Selzer F. Kip K.E. Beneficial effects of statins after percutaneous coronary intervention.Eur J Cardiovasc Prev Rehabil. 2009; 16: 445-450Crossref PubMed Scopus (15) Google Scholar]. A meta-analysis of randomized clinical trials consistently showed a similar magnitude of reduction in repeat revascularization with statin therapy which was initiated after PCI procedures (risk ratio: 0.73, 95% confidence interval: 0.55–0.98, P = 0.04) [[3]Zhang Z.J. Cheng Q. Jiang G.X. Marroquin O.C. Statins in prevention of repeat revascularization after percutaneous coronary intervention—a meta-analysis of randomized clinical trials.Pharmacol Res. 2010; 61: 316-320Crossref PubMed Scopus (9) Google Scholar]. As the authors pointed out in the Discussion, confounding cannot be completely controlled in an observational study due to unobserved covariates. Notably, several important prognostic factors in Tables 1 and 3 were not adjusted in their final multivariate model, although significant differences were observed between treatment groups. Small sample size may have limited the ability of a statistical model to accommodate covariates as needed. In this sense, adjustment through propensity score approach could possibly be an appropriate method to deal with their scenario [[4]Rosenbaum P.R. Rubin D.B. The central role of the propensity score in observational studies for causal effects.Biometrika. 1983; 70: 41-55Crossref Scopus (17259) Google Scholar].

Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart …

Early Statin Therapy and In-Hospital Outcomes in Acute Coronary Syndrome Patients Presenting with Advanced Killip Class at Admission: Findings from the CCC-ACS Project

The use of statins in acute coronary syndromes: the mechanisms behind the outcomes

Prescription of Statins at Discharge and 1‐year Risk of Major Clinical Outcomes among Acute Coronary Syndromes Patients with Extremely Low LDL‐cholesterol in Clinical Pathways for Acute Coronary Syndromes Studies

Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: A propensity-matched analysis of a global federated health database

Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention

Early statin use is associated with improved outcomes in patients with atrial fibrillation and recent ischaemic stroke.

Impact of Early Statin Therapy on Inhospital and Follow-Up Outcomes for Acute Coronary Syndrome Patients Undergoing Revascularization

Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data

Early Effect of Pravastatin on Serum Soluble CD40L, Matrix Metalloproteinase-9, and C-Reactive Protein in Patients with Acute Myocardial Infarction

Mortality Benefit and Reduced Need for Repeat Revascularization with Statin Therapy among Patients Undergoing Percutaneous Coronary Intervention

Benefits of Very Early Administration of Statins During the First Day of Hospitalization in Patients with Acute Myocardial Infarction

Early and extensive use of statins in patients with acute coronary syndrome

Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project.

Associations of Pre-Hospital Statin Treatment with In-Hospital Outcomes and Severity of Coronary Artery Disease in Patients with First Acute Coronary Syndrome-Findings from the CCC-ACS Project

Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction

Statin use before acute coronary syndrome and coronary risk factors, clinical presentation, interventions, and outcomes: ACC-NCDR-CathPCI Registry in India

Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.

Statin therapy associated mortality in hyperlipidemic dialysis patients with percutaneous coronary intervention for acute myocardial infarction, a retrospective cohort study

Associated Factors for Discontinuation of Statin Use One Year after Discharge in Patients with Acute Coronary Syndrome in China

Long-term Statin Use Before Primary Percutaneous Coronary Intervention Improves Treatment Outcomes of Acute Myocardial Infarction